AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3936056
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (20 mg, 3-times daily)
Trial: 3936056
Drug: Sustained-release glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release glyceryl trinitrate (6.4 mg, 3-times daily)
Trial: 30463925
Drug: Amoxicillin-Clavulanate (Amox-Clav)
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-Clavulanate (Amox-Clav)
Trial: 24637411
Drug: EPA (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (1800 mg/day) + statin (rosuvastatin)
Trial: 11945144
Drug: Leukocyte alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocyte alpha n‐3 interferon (IFN‐L)
Trial: 9718470
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg orally once daily for 3 days)
Trial: 9718470
Drug: Clarithromycin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (7.5 mg/kg orally twice daily for 10 days)
Trial: 2526959
Drug: Procaterol 0.02
RxNorm normalized name: procaterol 0.025 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol 0.02 mg
Trial: 2526959
Drug: Salbutamol 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 0.2 mg (control)
Trial: 332505
Drug: practolol 100
RxNorm normalized name: (±)-practolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: practolol 100 mg
Trial: 332505
Drug: practolol 400
RxNorm normalized name: (±)-practolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: practolol 400 mg
Trial: 31070702
Drug: Angiotensin-Converting Enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-Converting Enzyme Inhibitors (ACEis)
Trial: 22267465
Drug: darunavir/ritonavir (900/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir (900/100 mg once daily)
Trial: 22267465
Drug: raltegravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: raltegravir (400 mg twice daily)
Trial: 17224706
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER (3-15 mg once daily, starting dose = 9 mg)
Trial: 9733025
Drug: Antioxidant cocktail:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant cocktail: 90 mg of Q10 and 13.5 mg of d‐alpha‐tocopheryl acetate daily (18 men)
Trial: 8289481
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside (LD-AraC) 2 x 10 mg/m2 subcutaneously (s.c.) days 1‐14 plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) 2 x 150 micrograms protein/day s.c. given either following Ara C (days 15‐21) or simultaneously (days 8‐14) for 1‐5 cycles.
Trial: 8289481
Drug: Low-dose cytosine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytosine arabinoside (LD-AraC) alone (not explicitly mentioned but referenced as ongoing evaluation).
Trial: 1565294
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin E supplements (800 mg dl‐alpha‐tocopherol acetate) for 30 days
Trial: 755040
Drug: methysergide (serotonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methysergide (serotonin receptor blocker)
Trial: 30247332
Drug: Laparoscopic rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic rectal resection (Lap)
Trial: 30247332
Drug: Open laparotomy
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open laparotomy and rectal resection (Open)
Trial: 28086921
Drug: Web-based nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based nutrition education programme promoting vegetable intake (350 g per day, five small bowls)
Trial: 19438416
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once-daily
Trial: 19438416
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg twice-daily
Trial: 19438416
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once-daily
Trial: 19438416
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg twice-daily
Trial: 19438416
Drug: Esomeprazole (once-daily)
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole (once-daily) vs Lansoprazole (once-daily)
Trial: 19438416
Drug: Esomeprazole (twice-daily)
RxNorm normalized name: clindamycin
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole (twice-daily) vs Lansoprazole (twice-daily)
Trial: 17307447
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of indicated secondary prevention medications (antiplatelet agents, beta-blockers, ACE inhibitors or ARBs, lipid-lowering agents)
Trial: 17307447
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of indicated secondary prevention medications
Trial: 15362759
Drug: Perioperative music
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative music therapy with a key-lighting keyboard system (Group A)
Trial: 7983994
Drug: Oral homoeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral homoeopathic immunotherapy to their principal allergen
Trial: 24149925
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g of soy flour (whole soy group)
Trial: 24149925
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g of low-fat milk powder + 63 mg of daidzein (daidzein group)
Trial: 24149925
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g of low-fat milk powder (placebo group)
Trial: 18594318
Drug: Paclitaxel Poliglumex
RxNorm normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel Poliglumex (PPX) 175 mg/m
Trial: 18594318
Drug: Control (single-agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (single-agent vinorelbine or gemcitabine)
Trial: 16403289
Drug: Cationic propyl
RxNorm normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cationic propyl gallate (C‐PG) at 100‐300 micromol/L
Trial: 16403289
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) at 200‐400 mg
Trial: 12186195
Drug: Parenteral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral antibiotics prescription
Trial: 10822908
Drug: Carbohydrate solutions
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate solutions (HFG, LFG, GLU, BAN, SUG)
Trial: 10822908
Drug: Carbohydrate and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate and/or electrolytes in hydration solutions
Trial: 1628294
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control agent
Trial: 31294619
Drug: Diphencyprone immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphencyprone immunotherapy with intralesional meglumine antimoniate (MA)
Trial: 25273912
Drug: maximum doses
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: maximum doses of ARB
Trial: 22850442
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of rosuvastatin
Trial: 20440152
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Quixil sealant and marginal quilting sutures (group 2)
Trial: 18537963
Drug: Midazolam IV
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam IV (2 mg)
Trial: 18537963
Drug: Midazolam oral
RxNorm normalized name: midazolam Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam oral (7.5 mg)
Trial: 18537963
Drug: 1'-hydroxymidazolam oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1'-hydroxymidazolam oral
Trial: 30628526
Drug: Core stabilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core stabilization exercise therapy with bracing for 4 months
Trial: 23813218
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 µg/ml)
Trial: 23813218
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA; target trough level of 80-100 ng/ml)
Trial: 19203567
Drug: i.v. flumazenil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. flumazenil 0.005 mg/kg
Trial: 18077945
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of oral pravastatin daily for 14 days
Trial: 9640557
Drug: Regular AHA-blend
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular AHA-blend cream
Trial: 9640557
Drug: Extra strength
RxNorm normalized name: APAP Extra Strength
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra strength AHA-blend cream
Trial: 9640557
Drug: Control: non-AHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: non-AHA moisturizing lotion
Trial: 9922479
Drug: UDCA 300
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 300 mg per day (group II)
Trial: 9922479
Drug: UDCA 150
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 150 mg per day (group I)
Trial: 1833165
Drug: Nitrendipine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20-40 mg/day) for 24 months
Trial: 1833165
Drug: Captopril (75-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75-150 mg/day) for 24 months
Trial: 6136841
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (200 mg every 6 h from 8 days before to 35 days after bone-marrow transplantation)
Trial: 10793605
Drug: Saline 1
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 1 ml
Trial: 3527321
Drug: Oral ursodeoxycholic
RxNorm normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ursodeoxycholic acid for 48 h before surgery
Trial: 26596974
Drug: Micafungin 100
RxNorm normalized name: micafungin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 100 mg IV once daily
Trial: 26596974
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg IV once daily
Trial: 25001269
Drug: Trimetaphan (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetaphan (4 mg/min IV, autonomic blocked day)
Trial: 18377124
Drug: Family cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family cognitive‐behavioral therapy (FCBT)
Trial: 10594562
Drug: benznidazole therapy
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: benznidazole therapy
Trial: 1736755
Drug: Ethanol ingestion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol ingestion (2 ml/kg of 50% vodka)
Trial: 29397850
Drug: rhIL-11 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11 (1.5 mg/d)
Trial: 22399248
Drug: Mosapride (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride (15 mg/person/day) with PegIFN/RBV
Trial: 19887462
Drug: Intensive protocol-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive protocol-based strategy involving bi-weekly visits for 16 weeks with medication adjustments as needed.
Trial: 11999090
Drug: Diabetes (history
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes (history or fasting glucose > or =126 mg/dl)
Trial: 11999090
Drug: Dyslipidemia (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dyslipidemia (low HDL-cholesterol <40 mg/dl)
Trial: 11999090
Drug: High total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High total cholesterol (> or =200 mg/dl)
Trial: 11999090
Drug: High LDL-cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High LDL-cholesterol (> or =130 mg/dl)
Trial: 11999090
Drug: High triglycerides
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High triglycerides (> or =150 mg/dl)
Trial: 183084
Drug: Cholestyramine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine therapy with a low cholesterol diet
Trial: 183084
Drug: Out-patient follow-up
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-patient follow-up designed to reinforce patient motivation and dietary and drug adherence
Trial: 31406538
Drug: Intranasal steroids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal steroids, antihistamines, leukotriene antagonists (Group 1)
Trial: 26188833
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg combined with Simvastatin 10 mg (Vyto10)
Trial: 26188833
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg combined with Simvastatin 20 mg (Vyto20)
Trial: 26188833
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg alone (Simva20)
Trial: 23328284
Drug: Lactulose treatment
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose treatment (n = 32)
Trial: 23328284
Drug: Live binary
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live binary Bacillus subtilis treatment (n = 31)
Trial: 23328284
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (n = 34)
Trial: 18190369
Drug: Delayed feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed feeding (oral fluids 4 hours after surgery, diet at 24 hours)
Trial: 15673875
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 40 mg IM
Trial: 15673875
Drug: Morphine 12
RxNorm normalized name: morphine 120 mg/24 hours oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 12 mg IM
Trial: 15673875
Drug: Morphine 6
RxNorm normalized name: apomorphine 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 6 mg IM
Trial: 15673875
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment groups (Parecoxib sodium and morphine)
Trial: 10589357
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with cyclosporine (CSA) and methotrexate (MTX)
Trial: 1940189
Drug: Maalox TC
RxNorm normalized name: Aluminum Hydroxide/Magnesium Hydroxide 225 MG/5 ML-200 MG/5 ML Oral Suspension [MAALOX TC]
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maalox TC (1 tablet q.i.d., acid neutralizing capacity of 104 mEq/day)
Trial: 6210686
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g iv dose of mezlocillin
Trial: 6210686
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g iv dose of mezlocillin
Trial: 6210686
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g dose during haemodialysis (HD)
Trial: 27995880
Drug: Generic dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Generic dasatinib (100 mg dose)
Trial: 27995880
Drug: Reference dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Reference dasatinib (100 mg dose)
Trial: 20804269
Drug: Telephone-administered psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered psychotherapy for depression (16 weeks)
Trial: 18978165
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg zinc gluconate/d
Trial: 18978165
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg zinc gluconate/d
Trial: 18978165
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg zinc gluconate/d (placebo)
Trial: 12558609
Drug: Racemic salbutamol
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic salbutamol inhaled three times during a 6-h period
Trial: 12558609
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug treatment (control)
Trial: 10053176
Drug: Nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10 to 40 mg per day) with possible addition of enalapril (5 to 20 mg per day) or hydrochlorothiazide (12.5 to 25 mg per day) or both, titrated to reduce systolic blood pressure by at least 20 mm Hg and to less than 150 mm Hg.
Trial: 30952386
Drug: Combined intra‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intra‐ and postoperative tranexamic acid (TXA) treatment
Trial: 29394003
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch with replacement PIB adhesive (test)
Trial: 29394003
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch with previously used PIB adhesive (reference)
Trial: 22131101
Drug: Paquinimod (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paquinimod (4.5 mg/day and 6.0 mg/day)
Trial: 22131101
Drug: Paquinimod (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paquinimod (up to 3.0 mg/day)
Trial: 12067168
Drug: Combined antibiotics
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antibiotics (neomycin and metronidazole orally)
Trial: 12067168
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics (placebo)
Trial: 10508004
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 400 mg moxifloxacin
Trial: 10508004
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of 400 mg moxifloxacin over 60 min
Trial: 10508004
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of 400 mg moxifloxacin
Trial: 31272285
Drug: Transfection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfection of miR‐145‐5p inhibitor
Trial: 28846584
Drug: Preoperative interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative interventions (Expectation manipulation and Supportive therapy)
Trial: 26782835
Drug: Intense hypertension
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense hypertension treatment
Trial: 24421302
Drug: Alogliptin (ALO)
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin (ALO) 25 mg and Pioglitazone (PIO) 30 mg daily
Trial: 24421302
Drug: Alogliptin (ALO)
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin (ALO) 25 mg daily monotherapy
Trial: 17156824
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose HT (1 mg 17 beta‐estradiol + 0.5 mg norethisterone acetate)
Trial: 17156824
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose HT (2 mg 17 beta‐estradiol + 1 mg NETA)
Trial: 12484051
Drug: PHAI (5-FU:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHAI (5-FU: 500 mg/body/week for 50 cycles) plus oral UFT-E (400 mg/body/day for 24 months)
Trial: 7926076
Drug: Dydrogesterone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (60 mg)